Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06915753 · ClinicalTrials.gov registry record · Phase 1

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

A Phase 1 study of Advanced Solid Tumors and Solid Tumors, sponsored by Tyra Biosciences.

Recruiting
Registry status
Phase 1
Development phase
100
Enrollment target
16
Study locations

NCT06915753: Recruiting Phase 1 study of Advanced Solid Tumors and Solid Tumors, sponsored by Tyra Biosciences.

NCT06915753 is a Phase 1 study of Advanced Solid Tumors and Solid Tumors that is actively recruiting participants, run by Tyra Biosciences. The registered enrollment target is 100 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (49% lower). The trial reports 16 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06915753, a Phase 1 study of Advanced Solid Tumors and Solid Tumors, is actively recruiting participants, sponsored by Tyra Biosciences.

RECRUITING
Registry status
Phase 1
Development phase
100 participants
Enrollment target
16
Study locations

Study Summary

A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

Primary Outcome

MTD determination: dose limiting toxicity (DLT) rate in the first 28-day cycle

Conditions Studied

Advanced Solid Tumors Solid Tumors Solid Tumor, Adult Metastatic Hepatocellular Carcinoma FGFR3 Gene Mutation FGFR3 Gene Alteration FGFR Gene Amplification FGFR Gene Alterations FGFR4 Gene Mutation FGFR4 Gene Fusions

Interventions

  • DRUG TYRA-430

Study Locations (16)

Other

  • Asan Medical Center - Seoul
  • Samsung Medical Center - Seoul
  • Seoul National University Hospital - Seoul
  • Severance Hospital, Yonsei University Health System - Seoul
  • National Taiwan University Hospital - Taipei
  • Taipei Veterans General Hospital - Taipei

California

  • USC Norris Comprehensive Cancer Center - Los Angeles
  • UCSF Medical Center at Mount Zion - San Francisco
  • Stanford Cancer Institute - Stanford

Kansas

  • The University of Kansas Medical Center - Westwood

Maryland

  • John Hopkins University - Baltimore

Massachusetts

  • Mass General Cancer Center - Boston

Michigan

  • Karmanos Cancer Institute - Detroit

New York

  • Columbia University Irving Medical Center - New York

Tennessee

  • Sarah Cannon Research Institute Oncology Partners - Nashville

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-04-24
Est. Completion 2028-09
Phase Phase 1
Tyra Biosciences

6 total trials

What NCT06915753 shows while recruiting

NCT06915753 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (49% lower).

The record links to 10 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which TYRA-430 is the first listed.

NCT06915753 lists 16 locations in 9 states (Other, California, Kansas).

Frequently Asked Questions

What is clinical trial NCT06915753 about?

NCT06915753 is a clinical study titled "Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations". A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

What is the current status of trial NCT06915753?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2025-04-24. Estimated completion is 2028-09.

What conditions does trial NCT06915753 study?

This clinical trial studies the following conditions: Advanced Solid Tumors, Solid Tumors, Solid Tumor, Adult, Metastatic Hepatocellular Carcinoma, FGFR3 Gene Mutation.

What interventions are being tested in trial NCT06915753?

The interventions under investigation include: TYRA-430 (DRUG).

Who is sponsoring clinical trial NCT06915753?

This trial is sponsored by Tyra Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06915753 being conducted?

This trial has 16 study locations across California, Kansas, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06915753's enrollment target sits among peer trials

100 80th of 144 higher than 63 of 144 other Advanced Solid Tumors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06915753

Source: ClinicalTrials.gov NCT06915753, the US trial registry maintained by the National Library of Medicine. NCT06915753 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.